MaxCyte, Inc. Proceeds from Maturities, Prepayments and Calls of Short-term Investments
MaxCyte, Inc. (MXCT) reported Proceeds from Maturities, Prepayments and Calls of Short-term Investments of $313.77 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-12.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments · last filed 2024-03-12
- MaxCyte, Inc. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2023-06-30 was $74.32M, a 1043.38% increase year-over-year.
- MaxCyte, Inc. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2023-03-31 was $89.00M, a 55.68% decline year-over-year.
- MaxCyte, Inc. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2022-12-31 was $52.50M, a 5.41% decline year-over-year.
- MaxCyte, Inc. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2022-09-30 was $24.80M, a 313.33% increase year-over-year.
- MaxCyte, Inc. proceeds from maturities, prepayments and calls of short-term investments for fiscal 2023 was $313.77M, a 10.25% increase from fiscal 2022.
- MaxCyte, Inc. proceeds from maturities, prepayments and calls of short-term investments for fiscal 2022 was $284.60M, a 267.22% increase from fiscal 2021.
- MaxCyte, Inc. proceeds from maturities, prepayments and calls of short-term investments for fiscal 2021 was $77.50M, a 868.75% increase from fiscal 2020.
- MaxCyte, Inc. proceeds from maturities, prepayments and calls of short-term investments for fiscal 2020 was $8.00M, a 12.57% decline from fiscal 2019.
| Period end | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 3 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 6 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 9 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 12 month |
|---|---|---|---|---|
| 2023-12-31 | $313.77M 10-K · filed 2024-03-12 | |||
| 2023-06-30 | $74.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $163.32M 10-Q · filed 2023-08-09 | $215.82M derived: sum of 3 quarters · filed 2024-03-12 | $240.62M derived: sum of 4 quarters · filed 2024-03-12 |
| 2023-03-31 | $89.00M 10-Q · filed 2023-05-10 | $141.50M derived: sum of 2 quarters · filed 2024-03-12 | $166.30M derived: sum of 3 quarters · filed 2024-03-12 | $172.80M derived: sum of 4 quarters · filed 2024-03-12 |
| 2022-12-31 | $52.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $77.30M derived: sum of 2 quarters · filed 2024-03-12 | $83.80M derived: sum of 3 quarters · filed 2024-03-12 | $284.60M 10-K · filed 2024-03-12 |
| 2022-09-30 | $24.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $31.30M derived: sum of 2 quarters · filed 2023-08-09 | $232.10M 10-Q · filed 2022-11-09 | $287.60M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-06-30 | $6.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $207.30M 10-Q · filed 2023-08-09 | $262.80M derived: sum of 3 quarters · filed 2023-08-09 | $268.80M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $200.80M 10-Q · filed 2023-05-10 | $256.30M derived: sum of 2 quarters · filed 2023-05-10 | $262.30M derived: sum of 3 quarters · filed 2023-05-10 | $262.30M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $55.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $61.50M derived: sum of 2 quarters · filed 2023-03-15 | $61.50M derived: sum of 3 quarters · filed 2023-03-15 | $77.50M 10-K · filed 2023-03-15 |
| 2021-09-30 | $6.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $6.00M derived: sum of 2 quarters · filed 2022-11-09 | $22.00M 10-Q · filed 2022-11-09 | $27.50M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $16.00M 10-Q · filed 2022-08-10 | $21.50M derived: sum of 3 quarters · filed 2022-08-10 | $21.50M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $16.00M 10-Q · filed 2022-05-09 | $21.50M derived: sum of 2 quarters · filed 2022-05-09 | $21.50M derived: sum of 3 quarters · filed 2022-05-09 | |
| 2020-12-31 | $5.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $5.50M derived: sum of 2 quarters · filed 2022-03-22 | $8.00M 10-K · filed 2022-03-22 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $2.50M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $2.50M 10-Q · filed 2021-09-13 | |||
| 2019-12-31 | $9.15M 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |